A clinical trial to study the effect of Triflusal in Aspirin resitant patients

Assessment of efficacy and safety of Triflusal in ?Aspirin Resistant? patients with Type 2 Diabetes mellitus or documented Coronary Heart Disease (CHD)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2011/04/001679

Enrollment

Registered

2011-04-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Aspirin Resistant patients with Type 2 Diabetes mellitus or documented CHD

Interventions

Intervention1: Triflusal Capsules: Triflusal capsules 600mg once daily for one month Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: ?Patients with Type 2 Diabetes mellitus or documented Coronary Heart Disease on a stable dose of Aspirin# and detected to be having Aspirin Resistance. Stable dose of Aspirin - Patient on Aspirin on a particular dosage for more than 7 days. Aspirin Resistance - Determined by increased Thromboxane B2 (TxB2) levels in urine using AspirinWorks® Test Kit. ?Patients willing to provide informed consent and comply to the protocol.

Exclusion criteria

Exclusion criteria: ?Concomitant therapy with NSAIDs ?History of active peptic ulcer

Design outcomes

Primary

Measure	Time frame
Percentage decrease in TxB2 levels Percentage increase in cAMP levels Timepoint: one month of treatment with Triflusal 600mg OD	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr K Krishnaprasad

kkrishna@glenmarkpharma.com9820806811

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026